ZA200608877B - Combi nation dosing regimen for erythropoietin - Google Patents
Combi nation dosing regimen for erythropoietin Download PDFInfo
- Publication number
- ZA200608877B ZA200608877B ZA200608877A ZA200608877A ZA200608877B ZA 200608877 B ZA200608877 B ZA 200608877B ZA 200608877 A ZA200608877 A ZA 200608877A ZA 200608877 A ZA200608877 A ZA 200608877A ZA 200608877 B ZA200608877 B ZA 200608877B
- Authority
- ZA
- South Africa
- Prior art keywords
- epo
- dosing
- exposure
- segment
- administration
- Prior art date
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title description 246
- 102000003951 Erythropoietin Human genes 0.000 title description 11
- 108090000394 Erythropoietin Proteins 0.000 title description 11
- 229940105423 erythropoietin Drugs 0.000 title description 10
- 229940000425 combination drug Drugs 0.000 title 1
- 210000003743 erythrocyte Anatomy 0.000 claims description 71
- 210000001995 reticulocyte Anatomy 0.000 claims description 55
- 238000011282 treatment Methods 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 238000002512 chemotherapy Methods 0.000 claims description 8
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 231
- 102100031939 Erythropoietin Human genes 0.000 description 231
- 108010054147 Hemoglobins Proteins 0.000 description 61
- 102000001554 Hemoglobins Human genes 0.000 description 61
- 238000007920 subcutaneous administration Methods 0.000 description 42
- 238000004820 blood count Methods 0.000 description 39
- 238000000034 method Methods 0.000 description 22
- 229920001223 polyethylene glycol Polymers 0.000 description 19
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 230000035800 maturation Effects 0.000 description 14
- -1 such as via patch Chemical compound 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 11
- 206010021143 Hypoxia Diseases 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000007954 hypoxia Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 230000002459 sustained effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 7
- 108010074604 Epoetin Alfa Proteins 0.000 description 6
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 102000044890 human EPO Human genes 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 239000007943 implant Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001667 episodic effect Effects 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940029359 procrit Drugs 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000287 tissue oxygenation Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000012731 long-acting form Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55692304P | 2004-03-26 | 2004-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200608877B true ZA200608877B (en) | 2008-06-25 |
Family
ID=34964370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200608877A ZA200608877B (en) | 2004-03-26 | 2006-10-25 | Combi nation dosing regimen for erythropoietin |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20050267026A1 (ko) |
| EP (1) | EP1737484A1 (ko) |
| JP (1) | JP2007530578A (ko) |
| KR (1) | KR20070015549A (ko) |
| CN (1) | CN1960745A (ko) |
| AU (1) | AU2005231307A1 (ko) |
| BR (1) | BRPI0509239A (ko) |
| CA (1) | CA2561222A1 (ko) |
| CR (1) | CR8705A (ko) |
| EA (1) | EA010889B1 (ko) |
| EC (1) | ECSP066885A (ko) |
| IL (1) | IL178288A0 (ko) |
| MX (1) | MXPA06011084A (ko) |
| NO (1) | NO20064908L (ko) |
| UA (1) | UA89630C2 (ko) |
| WO (1) | WO2005097167A1 (ko) |
| ZA (1) | ZA200608877B (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150164991A1 (en) * | 2013-11-01 | 2015-06-18 | Vanderbilt University | Method and Kit for Evaluating and Monitoring a Treatment Program for Anemia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1367701A (zh) * | 1999-05-11 | 2002-09-04 | 奥索－麦克尼尔药物公司 | 红细胞生成素给药的药代动力学和药效模型 |
| NZ516735A (en) * | 1999-07-22 | 2004-01-30 | Aventis Pharma Inc | Multi-dose erythropoietin formulations containing benzethonium chloride as a preservative |
| DK1311285T4 (en) * | 2000-05-15 | 2017-07-24 | Hoffmann La Roche | Liquid pharmaceutical composition containing an erythropoietin derivative |
| US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
-
2005
- 2005-03-24 MX MXPA06011084A patent/MXPA06011084A/es unknown
- 2005-03-24 CA CA002561222A patent/CA2561222A1/en not_active Abandoned
- 2005-03-24 US US11/088,284 patent/US20050267026A1/en not_active Abandoned
- 2005-03-24 CN CNA2005800171911A patent/CN1960745A/zh active Pending
- 2005-03-24 KR KR1020067022204A patent/KR20070015549A/ko not_active Application Discontinuation
- 2005-03-24 AU AU2005231307A patent/AU2005231307A1/en not_active Abandoned
- 2005-03-24 UA UAA200610352A patent/UA89630C2/ru unknown
- 2005-03-24 WO PCT/US2005/009873 patent/WO2005097167A1/en active Application Filing
- 2005-03-24 JP JP2007505184A patent/JP2007530578A/ja active Pending
- 2005-03-24 BR BRPI0509239-6A patent/BRPI0509239A/pt not_active IP Right Cessation
- 2005-03-24 EP EP05731453A patent/EP1737484A1/en not_active Ceased
- 2005-03-24 EA EA200601782A patent/EA010889B1/ru not_active IP Right Cessation
-
2006
- 2006-09-25 IL IL178288A patent/IL178288A0/en unknown
- 2006-09-26 EC EC2006006885A patent/ECSP066885A/es unknown
- 2006-10-25 ZA ZA200608877A patent/ZA200608877B/en unknown
- 2006-10-25 CR CR8705A patent/CR8705A/es not_active Application Discontinuation
- 2006-10-26 NO NO20064908A patent/NO20064908L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005097167A1 (en) | 2005-10-20 |
| EP1737484A1 (en) | 2007-01-03 |
| IL178288A0 (en) | 2006-12-31 |
| CR8705A (es) | 2008-09-09 |
| AU2005231307A1 (en) | 2005-10-20 |
| MXPA06011084A (es) | 2007-03-21 |
| CA2561222A1 (en) | 2005-10-20 |
| ECSP066885A (es) | 2006-11-24 |
| EA010889B1 (ru) | 2008-12-30 |
| KR20070015549A (ko) | 2007-02-05 |
| US20050267026A1 (en) | 2005-12-01 |
| NO20064908L (no) | 2006-12-15 |
| BRPI0509239A (pt) | 2007-09-04 |
| CN1960745A (zh) | 2007-05-09 |
| EA200601782A1 (ru) | 2007-04-27 |
| JP2007530578A (ja) | 2007-11-01 |
| UA89630C2 (ru) | 2010-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2324494C2 (ru) | Новое применение эритропоэтина при сердечных заболеваниях | |
| ES2364651T3 (es) | Utilización de la eritropoyetina. | |
| US20030104996A1 (en) | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations | |
| US20030134798A1 (en) | Protection and enhancement of erythropoietin-responsive cells, tissues and organs | |
| KR20040064605A (ko) | 가스트린/ｃｃｋ 수용체 리간드 및 ｅｇｆ 수용체리간드를 함유하는, 섬 신생 유발을 위한 조성물 | |
| BG65417B1 (bg) | Приложение на еритропоетин или еритропоетинови производни за лечение на мозъчни исхемии | |
| US7459429B2 (en) | Method of treating disturbances of iron distribution in inflammatory intestinal diseases | |
| JP2007246530A (ja) | エリトロポエチン及び修飾ヘモグロビンを含んでいる医薬配合製剤 | |
| US7232797B2 (en) | Erythropoietin dosing regimen for treating anemia | |
| ZA200608877B (en) | Combi nation dosing regimen for erythropoietin | |
| WO2020010180A1 (en) | Compositions and methods for treating stroke | |
| US20070037886A1 (en) | Bone marrow erythroid progenitor cell(s) differentiation inducer | |
| Jelkmann | Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin (rhEPO) | |
| Lindberg | Improvements in anemia management with darbepoetin alfa, a new erythropoiesis stimulating protein |